EUVIMEDEUVIMED entdecken
Crossref

A novel DYRK1A inhibitor alleviates lipopolysaccharide-induced acute lung injury via suppressing inflammatory pathway

Xi Zeng, Lingyu Cui, Yetong Li, Xinhui Ye, Xiaoxuan Song, Han Wen, Chengkang Wang, Panpan Fan, Zixian Shen, Hui Huang, Junjie Lin, Tianqi Zhang und 4 weitere

International Immunopharmacology · 2026

DOI: 10.1016/j.intimp.2026.116300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Xi Zeng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, General Hospital of Northern Theater Command, Shenyang, China; Department of Pharmacy, the 78th Group Army Hospital …. Hauptthemen laut MEDLINE: Acute Lung Injury, Protein Serine-Threonine Kinases, Anti-Inflammatory Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acute lung injury (ALI) is a highly fatal inflammatory disease, lacking of safe and effective therapeutic drugs. Anti-inflammatory treatment is an effective strategy of ALI. PURPOSE: This study aimed to identify compound 24, a novel dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) inhibitor, as an anti-inflammatory agent for ALI. METHODS: We established the LPS-induced RAW 264.7 cell inflammation model and the mouse ALI model. ELISA and real time-PCR (RT-PCR) were used to detect the levels of inflammatory factors in supernatant and lung. Reactive oxygen species (ROS) production was measured by flow cytometry using DCFH-DA. HE was used to determine the pathological damage of lung. Immunohistochemistry was applied to detect inflammatory biomarkers in lung. The infiltration of inflammatory cells in bronchoalveolar lavage fluid (BALF) was determine by flow cytometry. Molecular docking, cellular thermal shift assay (CETSA), and western blot (WB) were conducted to measure the drug-target interaction and inflammatory signaling. RESULTS: Pretreatment with compound 24 significantly reduced the levels of inflammatory mediators including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), nitric oxide (NO), and ROS in vitro, and alleviated the release of inflammatory factors, infiltration of inflammatory cells, and tissue damage in the lung. Mechanistic studies indicated that compound 24 might exert its anti-inflammatory effect by targeting DYRK1A and inhibiting the TLR4/NF-κB signaling pathway. CONCLUSIONS: In summary, compound 24 exerted anti-inflammation effect with potential value for further development into a therapeutic drug for ALI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Lung InjuryProtein Serine-Threonine KinasesAnti-Inflammatory AgentsAnimalsDyrk KinasesLipopolysaccharidesMiceProtein-Tyrosine KinasesMaleRAW 264.7 CellsReactive Oxygen SpeciesSignal TransductionCytokinesLungDisease Models, AnimalNF-kappa BTyrosine Kinase InhibitorsMolecular Docking Simulation

Stichwörter der Autor:innen

ALIAnti-inflammatoryDYRK1ATLR4/NF-κB pathway

Substanzen

Protein Serine-Threonine KinasesDyrk KinasesLipopolysaccharidesProtein-Tyrosine KinasesAnti-Inflammatory AgentsReactive Oxygen SpeciesCytokinesNF-kappa BTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, General Hospital of Northern Theater Command, Shenyang, China; Department of Pharmacy, the 78th Group Army Hospital of Chinese PLA, Mudanjiang, China.
  • Department of Clinical Pharmacy, General Hospital of Northern Theater Command, Shenyang, China; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
  • Department of Clinical Pharmacy, General Hospital of Northern Theater Command, Shenyang, China; Department of Pharmacy, China Medical University, Shenyang, China.
  • Department of Clinical Pharmacy, General Hospital of Northern Theater Command, Shenyang, China; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China. Electronic address: bukuishini_hua122…
  • Department of Clinical Pharmacy, General Hospital of Northern Theater Command, Shenyang, China; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China. Electronic address: xuzihua-668585@16…
  • Department of Clinical Pharmacy, General Hospital of Northern Theater Command, Shenyang, China; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China. Electronic address: zhaoqingchun1967@…

Förderung

  • China Postdoctoral Science Foundation

Zitieren

APA

Zeng, X., Cui, L., Li, Y., Ye, X., Song, X., Wen, H., Wang, C., Fan, P., Shen, Z., Huang, H., Lin, J., Zhang, T., Abuduhalike, A., Chen, H., Xu, Z., & Zhao, Q. (2026). A novel DYRK1A inhibitor alleviates lipopolysaccharide-induced acute lung injury via suppressing inflammatory pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116300

Vancouver

Zeng X, Cui L, Li Y, Ye X, Song X, Wen H, et al. A novel DYRK1A inhibitor alleviates lipopolysaccharide-induced acute lung injury via suppressing inflammatory pathway. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116300

BibTeX
@article{Zeng2026,
  author = {Zeng, Xi and Cui, Lingyu and Li, Yetong and Ye, Xinhui and Song, Xiaoxuan and Wen, Han and Wang, Chengkang and Fan, Panpan and Shen, Zixian and Huang, Hui and Lin, Junjie and Zhang, Tianqi and Abuduhalike, Aihemaitijiang and Chen, Huanhua and Xu, Zihua and Zhao, Qingchun},
  title = {A novel DYRK1A inhibitor alleviates lipopolysaccharide-induced acute lung injury via suppressing inflammatory pathway},
  journal = {International Immunopharmacology},
  year = {2026},
  doi = {10.1016/j.intimp.2026.116300}
}
Kostenlos starten →